Healios K.K. to Present at the 2025 Jefferies Global Healthcare Conference

Company Overview - Healios K.K. is Japan's leading clinical stage biotechnology company focused on regenerative medicine using stem cells [3] - The company was established in 2011 and has been listed on the Tokyo Stock Exchange since 2015 under the TSE Growth Code 4593 [3] Product Development - Healios is developing a proprietary cell product called invimestrocel (HLCM051), which consists of multipotent adult progenitor cells (MAPCs) derived from the bone marrow of healthy adult donors [3] - The company is advancing invimestrocel for indications including ischemic stroke, acute respiratory distress syndrome (ARDS), and trauma [3] - Healios has confirmed its path to conditional approval in Japan for the use of invimestrocel for ARDS and is preparing to file for approval and commercial launch [3] Upcoming Events - Richard Kincaid, Chief Financial Officer of Healios, will present at the 2025 Jefferies Global Healthcare Conference on June 5, 2025, at 2:35 PM Eastern Standard Time [1] - A live and archived webcast of the presentation will be accessible from Jefferies' website, with a replay available for 60 days [2]